Pfizer Makes Plans For Interchangeable Adalimumab Filing
Company Sees Double-Digit Growth In Biosimilars Business In Q3 FY21
Pfizer has announced plans to file for an interchangeable biosimilar version of adalimumab in the US, ahead of its expected launch of its already-approved Humira biosimilar Abrilada (adalimumab-afzb) in July 2023. The company saw a jump of 36% in its biosimilars segment in Q3 on the back of recent launches.
